Errendszeri betegségek, spina bifida és schizophrenia egy családon belüli együttes elófordulása a metilén-tetrahidrofolsav-reduktáz enzim hóérzékeny variánsának heterozigóta mutációjával.

Translated title of the contribution: Vascular diseases, spina bifida and schizophrenia in a single family associated with the heterozygote mutation of the heat-sensitive variant of methylenetetrahydrofolate reductase

A. Horváth, Eva Morava-Kozicz, G. Tóth, M. Czakó, B. Melegh, G. Kosztolányi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Homozygous mutation of the thermolabile variant of methylene tetrahydrofolate reductase (MTHFR) may result in hyperhomocystinemia, leading to an increased risk for early cardiovascular disease, neural tube defects, and possibly major depression, schizophrenia. According to recent studies heterozygosity for the thermolabile variant of the MTHFR gene mutation is also more frequent in patients with thrombotic disease compared to that in the average population. We report on a family with different types of early vascular disease. In four consecutive generations MTHFR heterozygosity was detected: in the proband and in her mother, grandfather and daughter. Further conditions of the family members, possibly due to carrying the mutation, came to light by the pedigree analysis and examinations. The patient had pulmonary emboli at young age, her aunt died of spina bifida shortly after birth. The patient's mother suffers from schizophrenia and depression. The grandfather had pulmonary emboli, her sister with spina bifida occulta also carries the same mutation, as does her daughter who is sofar asymptomatic. In other asymptomatic members of the family no mutations were found. Unexpectedly, hyperhomocystinemia was detected in all heterozygote individuals. Our study demonstrates the necessity for folic acid therapy in mutation carriers to prevent early vascular events, depression and schizophrenia, and also to reduce the risk for neural tube defects in a preconception setting.

Original languageHungarian
Pages (from-to)1445-1448
Number of pages4
JournalOrvosi Hetilap
Volume142
Issue number27
StatePublished - Jul 8 2001
Externally publishedYes

Fingerprint

Methylenetetrahydrofolate Reductase (NADPH2)
Spinal Dysraphism
Heterozygote
Vascular Diseases
Schizophrenia
Hot Temperature
Mutation
Neural Tube Defects
Depression
Embolism
Nuclear Family
Spina Bifida Occulta
Mothers
Lung
Pedigree
Folic Acid
Blood Vessels
Siblings
Cardiovascular Diseases
Parturition

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Errendszeri betegségek, spina bifida és schizophrenia egy családon belüli együttes elófordulása a metilén-tetrahidrofolsav-reduktáz enzim hóérzékeny variánsának heterozigóta mutációjával. / Horváth, A.; Morava-Kozicz, Eva; Tóth, G.; Czakó, M.; Melegh, B.; Kosztolányi, G.

In: Orvosi Hetilap, Vol. 142, No. 27, 08.07.2001, p. 1445-1448.

Research output: Contribution to journalArticle

@article{2b4e324f2e7b4b2dbe01f267585ea119,
title = "Errendszeri betegs{\'e}gek, spina bifida {\'e}s schizophrenia egy csal{\'a}don bel{\"u}li egy{\"u}ttes el{\'o}fordul{\'a}sa a metil{\'e}n-tetrahidrofolsav-redukt{\'a}z enzim h{\'o}{\'e}rz{\'e}keny vari{\'a}ns{\'a}nak heterozig{\'o}ta mut{\'a}ci{\'o}j{\'a}val.",
abstract = "Homozygous mutation of the thermolabile variant of methylene tetrahydrofolate reductase (MTHFR) may result in hyperhomocystinemia, leading to an increased risk for early cardiovascular disease, neural tube defects, and possibly major depression, schizophrenia. According to recent studies heterozygosity for the thermolabile variant of the MTHFR gene mutation is also more frequent in patients with thrombotic disease compared to that in the average population. We report on a family with different types of early vascular disease. In four consecutive generations MTHFR heterozygosity was detected: in the proband and in her mother, grandfather and daughter. Further conditions of the family members, possibly due to carrying the mutation, came to light by the pedigree analysis and examinations. The patient had pulmonary emboli at young age, her aunt died of spina bifida shortly after birth. The patient's mother suffers from schizophrenia and depression. The grandfather had pulmonary emboli, her sister with spina bifida occulta also carries the same mutation, as does her daughter who is sofar asymptomatic. In other asymptomatic members of the family no mutations were found. Unexpectedly, hyperhomocystinemia was detected in all heterozygote individuals. Our study demonstrates the necessity for folic acid therapy in mutation carriers to prevent early vascular events, depression and schizophrenia, and also to reduce the risk for neural tube defects in a preconception setting.",
author = "A. Horv{\'a}th and Eva Morava-Kozicz and G. T{\'o}th and M. Czak{\'o} and B. Melegh and G. Kosztol{\'a}nyi",
year = "2001",
month = "7",
day = "8",
language = "Hungarian",
volume = "142",
pages = "1445--1448",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "27",

}

TY - JOUR

T1 - Errendszeri betegségek, spina bifida és schizophrenia egy családon belüli együttes elófordulása a metilén-tetrahidrofolsav-reduktáz enzim hóérzékeny variánsának heterozigóta mutációjával.

AU - Horváth, A.

AU - Morava-Kozicz, Eva

AU - Tóth, G.

AU - Czakó, M.

AU - Melegh, B.

AU - Kosztolányi, G.

PY - 2001/7/8

Y1 - 2001/7/8

N2 - Homozygous mutation of the thermolabile variant of methylene tetrahydrofolate reductase (MTHFR) may result in hyperhomocystinemia, leading to an increased risk for early cardiovascular disease, neural tube defects, and possibly major depression, schizophrenia. According to recent studies heterozygosity for the thermolabile variant of the MTHFR gene mutation is also more frequent in patients with thrombotic disease compared to that in the average population. We report on a family with different types of early vascular disease. In four consecutive generations MTHFR heterozygosity was detected: in the proband and in her mother, grandfather and daughter. Further conditions of the family members, possibly due to carrying the mutation, came to light by the pedigree analysis and examinations. The patient had pulmonary emboli at young age, her aunt died of spina bifida shortly after birth. The patient's mother suffers from schizophrenia and depression. The grandfather had pulmonary emboli, her sister with spina bifida occulta also carries the same mutation, as does her daughter who is sofar asymptomatic. In other asymptomatic members of the family no mutations were found. Unexpectedly, hyperhomocystinemia was detected in all heterozygote individuals. Our study demonstrates the necessity for folic acid therapy in mutation carriers to prevent early vascular events, depression and schizophrenia, and also to reduce the risk for neural tube defects in a preconception setting.

AB - Homozygous mutation of the thermolabile variant of methylene tetrahydrofolate reductase (MTHFR) may result in hyperhomocystinemia, leading to an increased risk for early cardiovascular disease, neural tube defects, and possibly major depression, schizophrenia. According to recent studies heterozygosity for the thermolabile variant of the MTHFR gene mutation is also more frequent in patients with thrombotic disease compared to that in the average population. We report on a family with different types of early vascular disease. In four consecutive generations MTHFR heterozygosity was detected: in the proband and in her mother, grandfather and daughter. Further conditions of the family members, possibly due to carrying the mutation, came to light by the pedigree analysis and examinations. The patient had pulmonary emboli at young age, her aunt died of spina bifida shortly after birth. The patient's mother suffers from schizophrenia and depression. The grandfather had pulmonary emboli, her sister with spina bifida occulta also carries the same mutation, as does her daughter who is sofar asymptomatic. In other asymptomatic members of the family no mutations were found. Unexpectedly, hyperhomocystinemia was detected in all heterozygote individuals. Our study demonstrates the necessity for folic acid therapy in mutation carriers to prevent early vascular events, depression and schizophrenia, and also to reduce the risk for neural tube defects in a preconception setting.

UR - http://www.scopus.com/inward/record.url?scp=0035827842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035827842&partnerID=8YFLogxK

M3 - Article

VL - 142

SP - 1445

EP - 1448

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 27

ER -